RT Journal Article
SR Electronic
T1 Benefits of Enhancing the Platinum-Free Interval in the Treatment of Relapsed Ovarian Cancer: More Than Just a Hypothesis?
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP S9
OP S11
DO 10.1097/IGC.0b013e318217b30b
VO 21
IS Supp 1
A1 Jonathan A. Ledermann
YR 2011
UL http://ijgc.bmj.com/content/21/Supp_1/S9.abstract
AB There is some evidence from in vitro studies as well as case series that patients with documented platinum resistance will respond to platinum after a nonplatinum drug. In addition, retrospective case studies have demonstrated the difficulty in determining if delaying second platinum is detrimental or beneficial. For that reason, a prospective Italian randomized trial conducted by the Multicenter Italian Trials in Ovarian Cancer (MITO) Group (MITO-8), comparing nonplatinum with platinum-based therapy is being performed to assess the effects of delaying platinum on survival.